ABSTRACT.Purpose: To compare intraocular pressure (IOP) readings taken using dynamic contour tonometry (DCT) with IOP readings taken with Goldmann applanation tonometry (GAT) in eyes with glaucoma or ocular hypertension. Methods: The present study included 100 eyes in 100 patients with glaucoma or ocular hypertension. After pachymetry DCT and GAT were performed. Intraocular pressures as measured with DCT and GAT were compared with one another and with central corneal thickness (CCT). Results: Mean DCT IOP measurements (20.1 ± 4.3 mmHg) were significantly (p < 0.001) higher than GAT IOP values (17.9 ± 4.7 mmHg). The mean difference between DCT and GAT measurements was 2.1 mmHg (range ) 3.4 to 9.7 mmHg). The difference followed a normal distribution. Measurements made with DCT and GAT correlated significantly with one another (Spearman's rho = 0.761, p < 0.001). Neither GAT nor DCT measurements showed a significant correlation with CCT (537 ± 39 lm, range 458-656 lm). Multivariate regression analysis has shown that the difference between DCT and GAT is influenced significantly by ocular pulse amplitude (r = ) 0.334, p = 0.001) and it is not influenced by CCT (r = ) 0.106, p = 0.292). Conclusions: In eyes with glaucoma or ocular hypertension, DCT facilitates suitable and reliable IOP measurements which are in good concordance with GAT readings. Variation in CCT cannot by itself explain the differences in measurements taken with DCT and GAT in a number of eyes.

Purpose. To present the case of a 27-year-old male patient with stage IV proliferative sickle cell retinopathy, treated with one intravitreal injection of ranibizumab, showing regression of the neovascularization and no recurrence at the 9-month follow-up. Methods. A 27-year-old male patient presented with blurred vision and floaters in the right eye since three days. His best corrected visual acuity was 6/18. Ophthalmological examination and fluorescein angiography revealed proliferative sickle cell retinopathy stage IV with vitreous hemorrhage and sea fan neovascularization, as well as ischemic areas at the temporal periphery. Results. The patient was treated with one intravitreal injection of ranibizumab, presenting improvement in the visual acuity from 6/18 to 6/6, resolution of vitreous hemorrhage, and regression of the neovascularization. Additionally, he underwent scatter laser photocoagulation at the ischemic areas. At the 9-month follow-up there was no recurrence, while no adverse effects were noticed. Conclusions. Intravitreal ranibizumab may be a useful adjunct to laser photocoagulation in the management of proliferative sickle cell retinopathy and may permit some patients to avoid pars plana vitrectomy for vitreous hemorrhage.

PurposeA preliminary study in order to test the accuracy of the IOL Master in detecting axial eye length changes after laser-assisted in situ keratomileusis and to correlate the findings with the theoretical ablation depth.MethodsPre-and postoperative axial eye length measurements were performed in 10 consecutive eyes that underwent laser-assisted in situ keratomileusis with the Alcon Ladar Vision excimer laser to treat myopic refractive errors ranging from −2.50 to −8.00 diopters of spherical equivalent (mean: −5.23 ± 1.30 D).ResultsThe preoperative axial eye length measurements ranged from 24.53 mm to 27.78 mm (mean: 25.80 ± 1.01 mm) and from 24.57 mm to 27.57 mm (mean: 25.68 ± 0.93 mm) 1 month after the operation. Preoperative and 1-month postoperative data showed a statistically significant difference (P < 0.05).ConclusionsThe IOL Master showed a decrease in the axial eye length measurements that was bigger than the theoretical ablation depth and did not correlate well with it. Such data need to be confirmed by a larger cohort of patients.

Purpose To evaluate changes in visual acuity after intravitreal injection of ranibizumab (0.5 mg) in patients with ischemic and non‐ischemic central retinal vein occlusion (CRVO). Methods In a retrospective study, 25 consecutive patients (25 eyes) where included, 15 eyes with ischemic CRVO and 10 eyes with non‐ischemic CRVO. Ophthalmic examination included decimal best corrected visual acuity (BCVA) and OCT at presentation and follow‐up visits. Changes on BCVA after treatment, in a period of follow up from 3 to 24 months, were evaluated. SPSS18 was used for statistical analysis. Results In ischemic CRVO group, patients’ mean age was 70.53 years. BCVA at presentation was 0.025 +/‐ 0.034 (mean +/‐SD), and BCVA at the last follow up was 0.072 +/‐ 0.13. The number of intravitreal injections performed was 3.07 +/‐ 2.12. In non‐ischemic CRVO group patients΄mean age was 69.60 years. BCVA at presentation was 0.33 +/‐ 0.22, and BCVA at the last follow up was 0.60 +/‐ 0.24. The number of intravitreal injections performed was 2.7+/‐ 1.2. In ischemic CRVO group there was no statistically significant improvement in visual acuity (0.046 +/‐ 0.13, paired t‐test p=0,186), whereas in non‐ischemic CRVO group the BCVA after treatment improved significantly (0.27 +/‐ 0.23 paired t‐test p=0,006). Conclusion Intravitreal ranibizumab injections in patients with CRVO may result in a significant improvement of BCVA in patients with non‐ischemic CRVO. Future prospective studies and a larger number of patients are needed to verify these results.

Purpose To investigate whether the ICare one rebound tonometer (ICRBT) can provide accurate measurements of intraocular pressure (IOP) in the hands of an inexperienced user and to compare ICare measurements with Goldman tonometry (GAT). Methods A trained examiner instructed each of 60 normal subjects on use of the ICRBT. Each subject then measured his/her own pressure using the ICRBT. Finally, a different examiner, who was masked to the earlier readings, measured IOP by GAT. Results All of the subjects were able to obtain accurate measurements with ICRBT after three attempts. Mean intraocular pressures (IOPs +/‐ SD) obtained using the two instruments were GAT 16.5 +/‐ 3.7 mmHg; and ICRBT 17.9 +/‐ 3.6 mmHg. The 95% LoA for ICRBT‐GAT were from ‐2,5 to +5.7 mmHg Conclusion The ICRBT was accurate and reliable in the hands of normal subjects and may be used for self monitoring of IOP.